HPPH Photodynamic Therapy for Patients With Esophageal Cancer
Status:
Unknown status
Trial end date:
2019-05-27
Target enrollment:
Participant gender:
Summary
Phase I study was to investigate the safety and tolerability of the photosensitizer (PS)
2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) for injection in patients with
Esophageal Cancer. It was to characterize the pharmacokinetics of HPPH and efficacy of HPPH.